Trials in set up

These are brief descriptions of trials currently in set up.  Information will be updated as soon as details are finalised, centres are known and the trials are starting.

Pamiparib and Low Dose Temozolomide In Patients with Platinum Sensitive Biliary Tract Cancer

In this study, all patients will have started on standard platinum (cisplatin or oxaliplatin) and gemcitabine chemotherapy. Patients whose disease is stable or has improved after 18 weeks of treatment will be eligible to be randomised to continue their chemotherapy (standard of care) or to receive a combination of Pamiparib and low-dose temozolomide.

Pamiparib is known as a PARP inhibitor, this stops the cancer cells from repairing from the damage caused by temozolomide, which is an oral chemotherapy drug. It is hoped that giving these two drugs together will be more toxic to the cancer cells and its effect will be compared to those patients receiving standard chemotherapy.

The study will be opening at Cambridge, Barts, Christie, Beatson and Royal Free

A Phase 2 study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with locally advanced/borderline resectable proximal biliary tract cancer.

This study will investigate the possible benefit of neo-adjuvant chemotherapy in those cholangiocarcinoma patients diagnosed with borderline resectability.

For more information see:

FOENIX-CCA3: An open-label, randomized Phase 3 study of futibatinib (TAS-120) versus gemcitabine-cisplatin chemotherapy as first-line treatment for patients with advanced cholangiocarcinoma harbouring fibroblast growth factor receptor 2 gene rearrangements (FOENIX-CCA3)

This study will compare chemotherapy (CisGem) with an FGFR-inhibitor in FGFR2-altered patients and will require prior analysis of a tumour biopsy to determine that there is the appropriate FGFR-alteration

Back to previous page